UTv Videos

Howard B. Goldman, MD, who was the first to use the device in a clinical setting, shares his initial thoughts on the technology and its role in real-world practice.

Clean intermittent catheterization emerged as the second most commonly used bladder management method over time in both sexes.

The course addresses "unicorn cases" in the upper tract—unique and challenging situations lacking established guidelines or literature.

Data showed that African American men faced significant delays in treatment initiation.

Vikram M. Narayan, MD, discusses Emory's recent shift to Apple products, aimed at reducing physician burnout and improving patient interactions.

Justin Dubin, MD, discussed how patients' growing trust in digital tools could be leveraged to support lifestyle changes and improve health outcomes.

Wang and Bukavina outline several cases of ctDNA's utility in the space.

Pezzella said she believes Neuspera offers a "smart, integrated, sophisticated alternative" for treating overactive bladder symptoms.

Mina M. Fam, MD, discusses some of the common misconceptions that patients have when seeking testosterone replacement therapy.

Benjamin M. Brucker, MD, outlines considerations surrounding pre-procedure urinalysis, prophylactic periprocedural antibiotics, and optimal dosing regimens for onabotA administration.

According to Daniel D. Joyce, MD, MS, policy initiatives should focus on improving the value and efficiency of radiation.

Anne K. Schuckman, MD, discusses some of the current challenges in delivering optimal care for patients with non–muscle invasive bladder cancer.

Justin M. Dubin, MD, outlines the current ways that artificial intelligence is being used in the male infertility space.

Bilal I. Chughtai, MD, walks through the design and potential implications of a pivotal trial of the Butterfly Prostatic Device.

Findings indicated that although trimodal therapy improved the quality of life for patients with muscle-invasive bladder cancer compared with cystectomy, its significantly higher cost made it not cost-effective.

A notable finding was that 35% of these NMIBC patients exhibited ctDNA positivity.

Vignesh T. Packiam, MD, outlines the mechanism of action for detalimogene voraplasmid as well as its potential benefits in terms of storage and dosing.

The most apparent risk factor is hours worked, as increased work hours directly correlate with heightened tiredness and stress.

McVary's expectation is that the results will be sustainable because the short-term outcomes for larger prostates appear superimposable on the longer-term outcomes for smaller, previously restricted prostate volumes

Justin Dubin, MD, touches on the current landscape of men’s health, with a specific focus on the advent of AI.

Laura E. Davis, MD, discusses the link between early onset prostate cancer and persistent poverty.

One prominent theory suggests that younger generations of graduating urologists face increased financial pressures due to higher student loan debt.

The ARASTEP trial is exploring the combination of darolutamide plus ADT vs ADT alone in patients with high-risk biochemical recurrence of prostate cancer.

The system is now cleared for use in prostates up to 150 cm3.

Amy E. Krambeck, MD, discusses how to define success and how to determine the optimal timing for adding on a new partner.

Olivares cautioned that HIFU is not suitable for all patients, particularly those with more aggressive disease, for whom complete gland removal may still be necessary.

“The takeaway is that on a population level, on a health care system perspective, it's more cost-effective and safer to do transperineal prostate biopsy,” says Mitchell M. Huang, MD.

David Stanley, MD, FACS, discusses current trends and unmet needs in the treatment of patients with kidney stones.